RT Journal Article
SR Electronic
T1 Early diagnosis and causal treatment of pneumonia associated with pandemic influenza A (H1N1) virus
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P568
VO 40
IS Suppl 56
A1 Sergei Lukyanov
A1 Vladimir Gorbunov
A1 Sergei Alexeev
A1 Michail Lazutkin
A1 Anatoly Govorin
A1 Elena Romanova
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P568.abstract
AB Introduction. In the conditions of epidemic of highly pathogenic virus a special role is taken away to early aetiological diagnosis of the disease. Meanwhile, expectation or absence of the result of RT-PCR can't be the reason for a delay of appointment of the antiviral therapy. Aim. The aim of the study was to investigate early diagnostic features of pneumonia associated with influenza A (H1N1) and the role of antiviral therapy.Methods. Retrospective analysis of the medical records of 135 patients with pneumonia associated with influenza A (H1N1) during October-December 2009 in Chita, RF. In all patients high resolution CT was developed. Antiviral therapy consisted of oseltamivir 150-300 mg or zanamivir 20 mg per day.Results. The greatest diagnostic value in laboratory confirmed cases of pneumonia associated with influenza A (H1N1) possessed following indicators: myalgia, leukopenia (4,0 or less), and a symptom of «matte glass».View this table:Diagnostic value of indicators of pneumonia associated with influenza A (H1N1)Antiviral therapy in the first 48 hours received 25 pts (18,5%). Duration of hospitalization in those patients was shorter - 8 [6; 11] in comparison of patients not receiving early antiviral therapy - 12 [9; 14,5] (p<0.01). An early initiation of oseltamivir reduced the risk of lethal outcome in 3 times, zanamivir - in 3,2 times (p<0.03).Conclusion. The greatest sensitivity and specificity in early diagnostic of influenza A(H1N1)-associated pneumonia was shown by the symptom of «matte glass». Antiviral medications, prescribed in due time can reduce risk of lethal outcome.